BioSpace News Archive

PolarityTE, Inc. (Nasdaq: PTE) is providing an update on a change to the strategic focus of the Company and the regulatory pathway for the Company’s SkinTE™ product.

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its first quarter 2020 operational and financial results on Thursday, May 7, 2020 after the U.S. financial markets close

Cortexyme, Inc. (Nasdaq: CRTX), a biopharmaceutical company developing treatments for Alzheimer’s disease (AD) and other degenerative diseases, today announced Caryn McDowell, J.D. will join the company’s executive leadership team as Chief Legal and Administrative Officer and Corporate Secretary, effective May 11, 2020.

ResMed Inc. (NYSE: RMD) (ASX: RMD), a world-leading digital health company, today announced results for its quarter ended March 31, 2020.

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced that it plans to release financial results for the first quarter 2020 before market open on Friday, May 8, 2020.

Today, Lonza Group Ltd hosted its Annual General Meeting, led by the Chairman of the Board of Directors, Albert M. Baehny.

BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019 with the U.S. Securities and Exchange Commission on April 30, 2020.

AMRI today announced its ongoing commitment to do its part in support of public health needs amidst the COVID-19 pandemic.

The U.S. Food and Drug Administration continued to take action in the ongoing response effort to the COVID-19 pandemic

Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of an underwritten public offering of 7,500,000 shares of common stock, no par value